Medical Weight Loss: The GLP-1 Science Explained
Medical weight loss programs have transformed how physicians approach obesity and metabolic disease. Unlike commercial diet plans, physician-supervised medical weight loss at SkinArtMD in Burnaby combines evidence-based pharmacotherapy with individualized lifestyle guidance — addressing the biology of weight regulation, not simply willpower. If you have heard about semaglutide, Ozempic, or Wegovy and wondered whether they might be right for you, this article breaks down the actual science: how these medications work at the cellular level, what peer-reviewed clinical trials show, and how a physician evaluates whether you are a suitable candidate.
Learn more about Medical Weight Loss
Our approach at SkinArtMD begins with a thorough physician consultation — because no medically sound program starts with a prescription alone.
What Is Medical Weight Loss?
Medical weight loss refers to physician-supervised strategies for achieving and maintaining clinically meaningful weight reduction, typically defined as five to ten percent or more of initial body weight. This threshold is significant: research consistently demonstrates that even modest reductions can substantially lower cardiometabolic risk — improving blood pressure, fasting glucose, HbA1c, and lipid panels in parallel with the number on the scale.
In contemporary practice, comprehensive medical weight loss programs integrate:
- GLP-1 receptor agonist pharmacotherapy — the primary pharmacological tool discussed here
- Nutritional counseling tailored to individual metabolic profile
- Behavioral support to sustain habit change over time
- Ongoing monitoring of metabolic biomarkers and medication tolerance
This is not a shortcut. It is a medical intervention governed by the same principles of informed consent, contraindication screening, and outcome monitoring as any clinical procedure.
Mechanism of Action: How GLP-1 Receptor Agonists Work
The GLP-1 Hormone — A Cellular Primer
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. It exerts multiple coordinated physiological actions:
- Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner — meaning it triggers insulin release only when blood glucose is elevated, a built-in safety mechanism that reduces hypoglycemia risk compared to older agents
- Suppresses glucagon release from pancreatic alpha cells, reducing hepatic glucose output
- Slows gastric emptying, prolonging satiety signals from the gut
- Acts centrally on hypothalamic appetite circuits — specifically the arcuate nucleus and nucleus tractus solitarius — to reduce food-seeking behavior and total caloric intake
In individuals with obesity, the normal postprandial GLP-1 surge is often blunted. GLP-1 receptor agonists (GLP-1 RAs) bypass this deficit by delivering pharmacological GLP-1 signaling at receptors throughout the body, with a substantially longer half-life than endogenous GLP-1 — which is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).
Semaglutide: The Current Clinical Standard
Semaglutide (marketed as Ozempic® for type 2 diabetes and Wegovy® for weight management) is a GLP-1 RA with approximately 94% structural homology to human GLP-1, modified with a C18 fatty diacid chain that enables reversible albumin binding. This engineering extends its half-life to approximately seven days, permitting once-weekly subcutaneous dosing — a major practical advantage over earlier daily-injection alternatives.
At weight-management doses, semaglutide's central nervous system effects become particularly pronounced. Neuroimaging studies have demonstrated reduced activation in dopaminergic reward-processing brain regions in response to food cues — attenuating not only physiological hunger but also the hedonic drive to eat. Patients often describe this as food simply feeling less compelling, rather than requiring willpower to resist.
Health Canada has approved semaglutide (at the chronic weight management dosing) for adults with obesity or overweight accompanied by at least one weight-related comorbidity. The FDA holds a parallel approval for the same indication. The lower-dose formulation (Ozempic®) carries separate Health Canada approval for type 2 diabetes management — a distinct indication with different dosing and monitoring considerations.
This distinction matters clinically: the dose, the indication, and the monitoring protocol differ between diabetic and non-diabetic populations. Physician oversight is not optional. Book a Consultation
Clinical Evidence: What Peer-Reviewed Trials Show
STEP 1 — Foundational Efficacy
Wilding et al., published in the New England Journal of Medicine, conducted the landmark STEP 1 trial evaluating semaglutide 2.4 mg weekly versus placebo in adults with overweight or obesity without diabetes. Participants receiving semaglutide achieved a mean body weight reduction of approximately 14.9% from baseline — more than triple the reduction seen with placebo. More than one-third of participants achieved 20% or greater weight loss. These results represented a substantial step-change from what had previously been achievable through non-surgical pharmacotherapy.
STEP 4 — The Discontinuation Question
Rubino et al., also in the New England Journal of Medicine, examined outcomes when semaglutide is withdrawn after an initial treatment period. Participants who transitioned to placebo regained approximately two-thirds of their lost weight within one year, while those who continued semaglutide maintained and extended their reductions. This finding carries critical implications for patient counseling: medical weight loss with GLP-1 therapy is a sustained intervention, not a finite course. Weight regain after stopping is biologically expected and should be discussed at the outset.
SELECT Trial — Cardiovascular Outcomes
Ryan et al., reporting in the New England Journal of Medicine, enrolled over 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide reduced major adverse cardiovascular events by approximately 20% versus placebo — repositioning GLP-1 therapy from a metabolic niche agent to a cardioprotective intervention with broad applicability. This trial fundamentally changed how obesity medicine is conceptualized in the evidence-based literature.
Taken together, these three trials establish semaglutide as among the most rigorously studied weight management agents in the history of metabolic pharmacotherapy.
Comparing GLP-1 Therapy to Adjacent Approaches
Understanding where GLP-1 therapy fits relative to alternatives helps patients make genuinely informed decisions:
| Approach | Mechanism | Average Weight Loss | Durability | Physician Required |
|---|---|---|---|---|
| Lifestyle modification alone | Caloric deficit, behavioral | 3–5% body weight | Low without ongoing support | Recommended |
| Orlistat (Xenical®) | GI lipase inhibitor | 3–5% body weight | Moderate | Yes |
| Liraglutide (Saxenda®) | GLP-1 RA — daily injection | ~5–8% body weight | Moderate | Yes |
| Semaglutide 2.4 mg (Wegovy®) | GLP-1 RA — weekly injection | ~12–17% body weight | High (with continuation) | Yes — physician |
| Bariatric surgery | Anatomical restriction / malabsorption | 25–35% body weight | High | Yes — surgical team |
Semaglutide bridges a clinically meaningful gap between lifestyle-only approaches and surgical intervention — offering substantial, sustained weight reduction without procedural risk. Orlistat's GI tolerability profile (fat malabsorption side effects) leads many patients to discontinue. Liraglutide requires daily injection and shows a more modest effect size than weekly semaglutide. Newer oral GLP-1 formulations are in development, but injectable semaglutide currently represents the most effective approved non-surgical pharmacotherapy available.
Candidate Evaluation: Who Qualifies?
At SkinArtMD, physician evaluation for medical weight loss is conducted by Dr. Sharon Fong, our CPSBC-registered physician specializing in aesthetic medicine and metabolic health. The evaluation process follows established obesity medicine guidelines:
Inclusion Criteria
- BMI ≥30 kg/m² (obesity classification), or
- BMI 27–29.9 kg/m² with at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease
- Adult patients with realistic expectations and genuine commitment to behavioral co-management
Contraindications and Cautions
GLP-1 receptor agonists are contraindicated or require careful consideration in the following contexts:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) — this is a black box warning for the entire GLP-1 RA class, based on preclinical rodent thyroid C-cell findings
- Active pancreatitis or history of severe pancreatitis — GLP-1 therapy should be avoided
- Pregnancy or planned pregnancy — weight loss pharmacotherapy is not appropriate during gestation
- Severe renal impairment beyond specified thresholds
- Significant GI motility disorders
The evaluation also screens for eating disorder history — GLP-1-induced appetite suppression requires careful navigation in patients with a history of restrictive eating patterns — as well as concurrent medications with interaction potential and baseline thyroid function.
Book a Consultation to begin a full physician assessment.
What to Expect: The Treatment Timeline
Patients in Burnaby entering the SkinArtMD medical weight loss program follow a structured, monitored protocol:
Phase 1 — Assessment (Week 0): Comprehensive consultation with history review, BMI calculation, and relevant laboratory work including thyroid panel, metabolic panel, and HbA1c. Full discussion of realistic expectations, timeline, and behavioral framework.
Phase 2 — Initiation (Weeks 1–4): Low starting dose to minimize GI side effects. Nausea — the most common early complaint — typically diminishes within two to four weeks as gastric accommodation develops.
Phase 3 — Dose Escalation (Months 1–5): Gradual titration per clinical response and individual tolerability. Most patients reach their maintenance dose over sixteen to twenty weeks.
Phase 4 — Maintenance and Monitoring (Month 6 Onward): Regular check-ins to assess weight trajectory, metabolic markers, side effect profile, and behavioral adherence. Dose adjustments made as clinically indicated.
Phase 5 — Long-term Strategy: Given what STEP 4 showed about weight regain after discontinuation, every program at SkinArtMD includes an honest, individualized conversation about sustained therapy versus transition planning.
Many of our patients in the Greater Vancouver area begin noticing meaningful changes in appetite and energy patterns within the first four to six weeks, with significant weight changes typically visible at the three-month mark — though individual results vary based on metabolic baseline, dietary adherence, and dose response.
Limitations and Adverse Effects
No medication is without limitations. Common adverse effects of GLP-1 RAs include:
- Nausea — most common, particularly during dose escalation; manageable with dose timing, meal composition adjustments, and graduated titration
- Constipation — addressed with adequate hydration, dietary fiber, and occasionally gentle stool softeners
- Reduced appetite — while therapeutically intended, can occasionally result in insufficient protein or micronutrient intake if dietary quality is not monitored
- Injection site reactions — typically mild and transient
Rare but serious adverse events to remain aware of:
- Acute pancreatitis — discontinue immediately if symptoms develop (severe epigastric pain radiating to the back)
- Gallbladder disease — cholelithiasis risk increases with rapid weight loss by any mechanism, not specific to GLP-1 therapy
- Potential ocular signals — regulatory agencies including Health Canada are actively monitoring emerging reports; patients with pre-existing eye disease should discuss this with their physician
Cost and medication access represent real-world barriers for many patients. Semaglutide at weight-management doses is not universally covered by BC provincial drug plans, and supply has periodically been constrained. A physician consultation at SkinArtMD will address current coverage options. Contact us for current pricing.
Why Choose SkinArtMD for Medical Weight Loss?
Clinics across the Greater Vancouver area offer weight loss programs. What distinguishes the physician-led approach at SkinArtMD:
Physician-led, not protocol-driven. Dr. Fong's CPSBC registration means your care is governed by the same regulatory standards as any licensed BC physician — not a standardized algorithm operated by non-physician staff.
Integrated aesthetic and metabolic perspective. Weight loss affects skin laxity, facial volume, and body contour. At SkinArtMD in Burnaby, we think holistically about what physical transformation means for you — and can address skin and body contouring considerations as part of a comprehensive care plan.
Bilingual care. Our team serves English- and Mandarin-speaking patients. For patients in the Metro Vancouver Chinese community, navigating medical conversations in your preferred language matters. 我们提供普通话和英语双语医疗服务。
Genuinely personalized. Patients often tell us that previous programs felt generic. Our initial consultation is a thorough, individualized conversation — not a checkbox exercise.
Accessible Burnaby location. Conveniently located near Metrotown, easily reached from across Burnaby, New Westminster, Richmond, and Vancouver.
Book your complimentary consultation at SkinArtMD
Frequently Asked Questions
How is medical weight loss different from purchasing semaglutide through an online pharmacy? Physician oversight provides systematic contraindication screening, appropriate dose selection, monitoring for adverse effects, and integration with behavioral support. Prescriptions issued without proper in-person evaluation carry meaningful medical risk and are increasingly subject to regulatory action in Canada.
How quickly will I see results? Results vary significantly by individual — baseline metabolism, dietary patterns, dose tolerance, and genetic factors all influence the trajectory. In clinical trials, meaningful weight loss (5% or more of body weight) was typically observed within eight to twelve weeks of reaching effective doses.
Is long-term semaglutide use safe? The SELECT trial demonstrated sustained benefit and acceptable safety over approximately three years of follow-up. Long-term data beyond five years continue to accumulate. At SkinArtMD, ongoing benefit-risk reassessment is built into the program structure.
Will I regain weight if I stop the medication? The STEP 4 data clearly show that a significant proportion of weight lost returns after discontinuation — this is biologically expected. GLP-1 therapy modulates appetite set-points that trend back toward baseline when medication is withdrawn. Long-term strategy planning is therefore an explicit component of our program, not an afterthought.
Can I combine this program with aesthetic treatments? Many SkinArtMD patients integrate medical weight loss with body contouring or skin tightening procedures. Sequence and timing depend on individual goals and are discussed during consultation.
Does BC insurance cover semaglutide for weight loss? Coverage varies significantly by plan and differs from the diabetes indication. Our team can guide you through documentation requirements and any applicable appeal processes. Contact us for current pricing and coverage guidance.
Next Steps
If you have read this far, you are doing precisely what an informed patient should: understanding the biology before making a decision. The next step is a physician-level conversation tailored to your specific health history, goals, and current medications.
At SkinArtMD in Burnaby, medical weight loss consultations are conducted directly by Dr. Fong — not delegated to non-physician staff. Consultation spots are limited; we recommend booking in advance to secure your preferred time.
Ready to See What Medical Weight Loss Can Do for You?
Our medical team at SkinArtMD in Burnaby is ready to create your personalized treatment plan. Book your complimentary consultation today — available in English and Chinese.
This article is for educational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional before undergoing any treatment.
